Kong H - Search Results

1

A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.

Yi K, Kong H, Zheng C, Zhuo C, Jin Y, Zhong Q, Mintz RL, Ju E, Wang H, Lv S, Lao YH, Tao Y, Li M. Yi K, et al. Among authors: kong h. Biomaterials. 2023 Nov;302:122349. doi: 10.1016/j.biomaterials.2023.122349. Epub 2023 Oct 6. Biomaterials. 2023. PMID: 37844429

2

Editorial: Synthesis, Functionalization, and Clinical Translation of Pharmaceutical Biomaterials.

Kong H, Lv S, Li M, Ding J. Kong H, et al. Front Bioeng Biotechnol. 2021 Jun 21;9:707963. doi: 10.3389/fbioe.2021.707963. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34235140 Free PMC article. No abstract available.

3

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.

Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Kong H, et al. Adv Sci (Weinh). 2021 Dec;8(24):e2102051. doi: 10.1002/advs.202102051. Epub 2021 Oct 19. Adv Sci (Weinh). 2021. PMID: 34665528 Free PMC article. Review.

4

Membrane-fusogenic biomimetic particles: a new bioengineering tool learned from nature.

Kong H, Yi K, Zheng C, Lao YH, Zhou H, Chan HF, Wang H, Tao Y, Li M. Kong H, et al. J Mater Chem B. 2022 Sep 21;10(36):6841-6858. doi: 10.1039/d2tb00632d. J Mater Chem B. 2022. PMID: 35781483 Review.

5

Membrane-Fusion-Mediated Multiplex Engineering of Tumor Cell Surface Glycans for Enhanced NK Cell Therapy.

Zheng C, Zhong Q, Song W, Yi K, Kong H, Wang H, Tao Y, Li M, Chen X. Zheng C, et al. Among authors: kong h. Adv Mater. 2023 Apr;35(14):e2206989. doi: 10.1002/adma.202206989. Epub 2023 Jan 15. Adv Mater. 2023. PMID: 36566024

6

Microneedle system for tissue engineering and regenerative medicine.

Zhang Y, Xu Y, Kong H, Zhang J, Chan HF, Wang J, Shao D, Tao Y, Li M. Zhang Y, et al. Among authors: kong h. Exploration (Beijing). 2023 Jan 21;3(1):20210170. doi: 10.1002/EXP.20210170. eCollection 2023 Feb. Exploration (Beijing). 2023. PMID: 37323624 Free PMC article. Review.

7

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy.

Yi K, Kong H, Lao YH, Li D, Mintz RL, Fang T, Chen G, Tao Y, Li M, Ding J. Yi K, et al. Among authors: kong h. Adv Mater. 2024 Mar;36(13):e2300665. doi: 10.1002/adma.202300665. Epub 2023 Dec 12. Adv Mater. 2024. PMID: 37437039 Review.

8

Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy.

Zheng C, Zhong Q, Yi K, Kong H, Cao F, Zhuo C, Xu Y, Shi R, Ju E, Song W, Tao Y, Chen X, Li M. Zheng C, et al. Among authors: kong h. Sci Adv. 2023 Aug 9;9(32):eadh2413. doi: 10.1126/sciadv.adh2413. Epub 2023 Aug 9. Sci Adv. 2023. PMID: 37556535 Free PMC article.

9

CRISPR/Cas detection with nanodevices: moving deeper into liquid biopsy.

Kong H, Yi K, Mintz RL, Wang B, Xu Y, Lao YH, Tao Y, Li M. Kong H, et al. Chem Commun (Camb). 2024 Feb 22;60(17):2301-2319. doi: 10.1039/d3cc05375j. Chem Commun (Camb). 2024. PMID: 38251733 Review.

10

An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo.

Kong H, Zheng C, Yi K, Mintz RL, Lao YH, Tao Y, Li M. Kong H, et al. Nat Commun. 2024 May 20;15(1):4267. doi: 10.1038/s41467-024-46533-z. Nat Commun. 2024. PMID: 38769317 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,770 results

Search Page

Filters